Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKinsey
Medtronic
Moodys
Express Scripts

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

BREVIBLOC Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Brevibloc patents expire, and when can generic versions of Brevibloc launch?

Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in twenty-four countries.

The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

Drug patent expirations by year for BREVIBLOC
Drug Prices for BREVIBLOC

See drug prices for BREVIBLOC

Recent Clinical Trials for BREVIBLOC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cristália Produtos Químicos Farmacêuticos Ltda.Phase 4
University Hospital Bispebjerg and FrederiksbergPhase 4
Samuel BrownPhase 2

See all BREVIBLOC clinical trials

Recent Litigation for BREVIBLOC

Identify potential future generic entrants

District Court Litigation
Case NameDate
BAXTER HEALTHCARE CORPORATION v. AGILA SPECIALTIES PRIVATE LIMITED2014-11-12
BAXTER HEALTHCARE CORPORATION v. HQ SPECIALTY PHARMA CORPORATION2013-10-18
BAXTER HEALTHCARE CORPORATION v. AGILA SPECIALTIES PRIVATE LIMITED

See all BREVIBLOC litigation

PTAB Litigation
PetitionerDate
Mylan Pharmaceuticals Inc.2015-11-19

See all BREVIBLOC litigation

Pharmacology for BREVIBLOC
Synonyms for BREVIBLOC
(+-)-Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate hydrochloride
(+/-)-methyl p-[2-hydroxy-3-(isopropylamino) propoxy]hydrocinnamate hydrochloride
4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoic acid methyl ester HCl
4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benxzenepropanoic Acid Methyl Ester Hydrochloride
4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester hydrochloride hydrochloride
598E034
81147-92-4 (Parent)
81161-17-3
81161-17-3, 81147-92-4(free base)
AB0013228
AB07716
AC-6972
AC1L2XGQ
AC1Q3EA6
AKOS015895316
AN-9460
API0001758
Asl 8052
ASL-8052
BCP28434
Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester, hydrochloride
Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester, hydrochloride, (+-)-
Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester,hydrochloride
BG0502
Brevibloc (TN)
Brevibloc Double Strength in plastic container
Brevibloc in plastic container
C16H25NO4.HCl
CAS-81161-17-3
CCG-100972
CCG-220890
CHEBI:4857
CHEMBL1201115
CPD000469141
CS-4908
CTK8F9497
D00644
DSSTox_CID_28929
DSSTox_GSID_49003
DSSTox_RID_83195
DTXSID7049003
EBD13377
Esmolol (hydrochloride)
Esmolol HCL
Esmolol hydrochloride
Esmolol hydrochloride (JAN/USAN)
Esmolol hydrochloride [USAN]
Esmolol hydrochloride, >=98% (HPLC), solid
Esmolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
Esmolol(hydrochloride)
FT-0082446
FT-0601541
H746
HSDB 6530
HY-B1392
I06-0682
J-003862
KS-00001FBX
KS-1353
LS-31122
methyl 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoate hydrochloride
methyl 3-(4-{2-hydroxy-3-[(methylethyl)amino]propoxy}phenyl)propanoate, chlori de
METHYL 3-[4-(2-HYDROXY-3-PROPAN-2-YLAMINO-PROPOXY)PHENYL]PROPANOATE HYDROCHLORIDE
Methyl 3-[4-(2-hydroxy-3-propan-2-ylamino-propoxy)phenyl]propanoate hydrochloride; Brevibloc
methyl 3-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]propanoate hydrochloride
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate hydrochloride
Methyl 3-{4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl}propanoate hydrochloride (Esmolol HCl)
MLS001401393
MolPort-003-847-093
NC00222
NCGC00185766-01
NCGC00185766-04
Q-201070
s4100
SAM001246533
SBB055181
SCHEMBL41086
SMR000469141
SR-01000763706
SR-01000763706-4
SW197602-3
TL8005428
Tox21_113496
Tox21_113496_1
W-1240

US Patents and Regulatory Information for BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988 DISCN No No   See Pricing   See Pricing   See Pricing
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 RX Yes Yes   See Pricing   See Pricing Y   See Pricing
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 DISCN No No   See Pricing   See Pricing Y   See Pricing
Baxter Hlthcare BREVIBLOC IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-004 Feb 16, 2001 RX Yes Yes   See Pricing   See Pricing Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988   See Pricing   See Pricing
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988   See Pricing   See Pricing
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003   See Pricing   See Pricing
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BREVIBLOC
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags ➤ Subscribe   See Pricing

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Express Scripts
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.